These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38558722)

  • 1. Light-Chain (AL) Cardiac Amyloidosis Presenting as Heart Failure With Reduced Ejection Fraction.
    Santiago LE; Alvi AT; Melnychuk V; Mesquita P; Aneja P
    Cureus; 2024 Feb; 16(2):e55271. PubMed ID: 38558722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Diagnostic Modalities in an Isolated Case of Cardiac Amyloidosis.
    Lewars J; Wazir H; Gordon B; Faluyi U; Girgis Y
    Cureus; 2021 Apr; 13(4):e14608. PubMed ID: 34040908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.
    Ton VK; Mukherjee M; Judge DP
    Clin Med Insights Cardiol; 2014; 8(Suppl 1):39-44. PubMed ID: 25628512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-Type Transthyretin Amyloidosis: A Prevalent and Underdiagnosed Cause of Heart Failure With Preserved Ejection Fraction.
    Stehlik B; Sideris K; Brinker L; Waldron J; Carter S
    Cureus; 2024 Jun; 16(6):e62623. PubMed ID: 39027769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis.
    Perlini S; Salinaro F; Musca F; Mussinelli R; Boldrini M; Raimondi A; Milani P; Foli A; Cappelli F; Perfetto F; Palladini G; Rapezzi C; Merlini G
    J Hypertens; 2014 May; 32(5):1121-31; discussion 1131. PubMed ID: 24509117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid Light-Chain Amyloidosis Manifesting as Heart Failure with Preserved Ejection Fraction in a Patient with Hyper-Immunoglobulin E-emia.
    Nojima Y; Ihara M; Kurimoto T; Nanto S
    Am J Case Rep; 2016 Apr; 17():235-40. PubMed ID: 27064109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy.
    Murat S; Çavuşoğlu Y; Ak Sivrikoz İ
    Turk Kardiyol Dern Ars; 2021 Oct; 49(7):579-584. PubMed ID: 34623301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent Heart Failure Despite Medical Therapy Leading to a Diagnosis of Cardiac Amyloidosis.
    Maraj D; Ramanan S; Patel PM; Memon M; Hawes E
    Cureus; 2023 Aug; 15(8):e43547. PubMed ID: 37719596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
    Manolis AS; Manolis AA; Manolis TA; Melita H
    Eur J Intern Med; 2019 Sep; 67():1-13. PubMed ID: 31375251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
    Perlini S; Mussinelli R; Salinaro F
    Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac amyloid presenting as cardiogenic shock: case series.
    Oye M; Dhruva P; Kandah F; Oye M; Missov E
    Eur Heart J Case Rep; 2021 Jul; 5(7):ytab252. PubMed ID: 34377906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the diagnosis and management of amyloid cardiomyopathy.
    Nijst P; Tang WW
    Fac Rev; 2021; 10():31. PubMed ID: 33817700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.
    Kaiser ME; Lewis TJ
    Cureus; 2023 Dec; 15(12):e50527. PubMed ID: 38098740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure.
    Molina O G; Judge D; Campbell W; Chahal H; Mugmon M
    J Community Hosp Intern Med Perspect; 2014; 4(5):25500. PubMed ID: 25432650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac amyloidosis.
    Martinez-Naharro A; Hawkins PN; Fontana M
    Clin Med (Lond); 2018 Apr; 18(Suppl 2):s30-s35. PubMed ID: 29700090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Senile Systemic Amyloidosis: An Underdiagnosed Disease.
    Manso MC; Marques DP; Rocha SL; Rodeia SC; Domingos R
    Eur J Case Rep Intern Med; 2017; 4(9):000725. PubMed ID: 30755970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
    Halatchev IG; Zheng J; Ou J
    J Thorac Dis; 2018 Mar; 10(3):2034-2045. PubMed ID: 29707360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.